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or the elderly who are most affected by inﬂuenza, and to
ncrease vaccine coverage in younger adults. The intrader-
al route of vaccination provides a direct and potentially
ore efﬁcient access to the immune system. An ID TIV
as developed with a unique, convenient microinjection
ystem, and 2 dosage presentations speciﬁcally for elderly
nd younger adults (respectively 15g or 9g hemagglu-
inin/strain/dose).
Methods: The immunogenicity and safety of the two
resentations of ID TIV have been investigated in sev-
ral large-scale Phase 2 and 3 studies in several European
ountries, Australia and New Zealand. In each study, a
icensed intramuscular TIV, (Vaxigrip®; 15g hemagglu-
inin/strain/dose) was used as a control. Safety evaluation
ncluded documentation of solicited and unsolicited reac-
ions. Hemagglutination inhibition responses were evaluated
n D0 and D21.
Results: Phase 2 studies in more than 2000 subjects aged
8—60 years or >60 years have demonstrated that the 15g
D intradermal vaccination induces higher immune responses
ompared with Vaxigrip against all three strains, as assessed
y D21 GMTs and seroprotection rates. Among younger
dults, the 9g intradermal vaccine was demonstrated to
nduce an equivalent immune response to Vaxigrip.
Safety results showed that both ID vaccine presentations
ere well tolerated. When 18—60 year olds, subjects were
accinated a second time either ID or IM, one year after
heir ﬁrst vaccination, reactogenicity was not enhanced
ompared with that observed after the ﬁrst vaccination.
Conclusion: Using microinjection to deliver antigen via
he less-invasive intradermal route, ID TIV was shown to
licit superior immune responses to conventional vaccine in
lderly adults, and provides an alternative vaccine for adults
hat may encourage increased vaccine uptake.
oi:10.1016/j.ijid.2008.05.088
9.004
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ackground & Objectives: The identiﬁcation of immunolog-
cal surrogate markers of protection against disease plays
key role in the assessment of the efﬁcacy of any vaccine.
he sole identiﬁcation of an appropriate surrogate marker is
owever not sufﬁcient to provide an accurate prediction of
accine efﬁcacy. A statistical model providing a reliable esti-
ation of the relationship between this marker and clinical
rotection is also required. We review analyses and mod-
ls that explore this relationship in the case of inﬂuenza.
e then discuss the application of such models to estimate
he gain in efﬁcacy provided by a novel seasonal inﬂuenza
accine given by intradermal microinjection.
Methods & Principal ﬁndings: Several markers have been
sed to assess the immunogenicity of inﬂuenza vaccines.
nti-haemagglutinin antibodies, measured by the haemag-
lutination inhibition (HI) assay is however the only one for
hich attempts have been made to quantify its relationship
ith protection against clinical inﬂuenza. Seminal analyses
i
a
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ocused on the identiﬁcation of an HI titre level that can be
ssociated with either a 50% reduction (1:40) or a 90% reduc-
ion (1:92) in the risk of inﬂuenza. More recently, a model
sing published data from 15 studies, conﬁrmed the signiﬁ-
ant and positive relationship existing between HI titre and
linical protection against inﬂuenza and provided an esti-
ate of the level of protection against inﬂuenza for any
I titer. When applied to immunogenicity data from clinical
rials with an trivalent, inactivate inﬂuenza vaccine given
y intradermal microinjection, this model predicts a gain
n vaccine efﬁcacy of 14% (95% CI: 10—18) compared with
onventional non-adjuvanted inactivated inﬂuenza vaccines
iven intramuscularly.
Conclusions: Statistical models estimating the relation-
hip between HI data and level of protection against
nﬂuenza provide useful information to predict vaccine efﬁ-
acy, particularly for comparing vaccines based on their
mmunological proﬁle.
oi:10.1016/j.ijid.2008.05.089
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pproximately 170 million people world wide are infected
ith Hepatitis C virus (HCV). The therapy of hepatitis C
as gone through various phases of development. In the
arly 90s, therapy was empirical and standard interferon
as given initially for 6 months and then for 12 months. Then
ame along ribavirin, a guanosine analog and an oral drug,
hich administered with interferon improved sustained viro-
ogic response rates and this primarily was achieved by
ecreasing relapse rates. The current standard of care as
herapy for Hepatitis C consists of pegylated interferon-alfa
nd ribavirin. In genotype 1 patients, sustained virologic
esponse rates have been around 40—60% after 48 weeks
f therapy whereas non-1 patients, primarily made up of
enotypes 2 and 3, have an approximate 80% probability
f sustained virology response after 24 weeks of therapy.
lthough treatment duration has traditionally been ﬁxed,
here is a paradigm of virologic response guided therapy
hat has evolved. For rapid virologic responders, charac-
erized as HCV RNA negativity at week 4, reports suggest
hat 12—16 weeks of therapy for genotype 2 patients and 24
eeks of therapy for genotype 1 patients may be adequate.
n contrast, in genotype 1 patients who have a slow response
haracterized by a loss of HCV RNA at week 24, a prolonged
ourse of 72 weeks is the optimal regimen. Despite these
dvances, there is an unmet need for better therapies in the
on-responders, in those with advanced and decompensated
iver disease, in those with a spectrum of special situations
uch as transplantation etc, and those who do not tolerate
nterferon and ribavirin. Thus there is a need for novel ther-
pies with enhanced efﬁcacy, tolerability, and greater ease
f administration.
We now stand at the edge of an exciting phase with
he advent of Speciﬁcally Targeted Antiviral Therapy for
